Metsera (NASDAQ:MTSR - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($1.03) EPS for the quarter, Zacks reports.
Metsera Stock Up 15.3%
Metsera stock traded up $3.91 during mid-day trading on Friday, reaching $29.52. 1,043,711 shares of the company's stock were exchanged, compared to its average volume of 872,445. Metsera has a twelve month low of $12.30 and a twelve month high of $32.81. The stock's fifty day simple moving average is $22.86.
Analyst Ratings Changes
Several equities analysts have recently weighed in on the company. Cantor Fitzgerald assumed coverage on Metsera in a report on Tuesday, February 25th. They set an "overweight" rating on the stock. Bank of America assumed coverage on shares of Metsera in a report on Tuesday, February 25th. They issued a "buy" rating and a $38.00 price target for the company. Evercore ISI started coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued an "outperform" rating for the company. Finally, Guggenheim initiated coverage on shares of Metsera in a research report on Tuesday, February 25th. They set a "buy" rating and a $56.00 target price on the stock.
Read Our Latest Report on Metsera
Institutional Investors Weigh In On Metsera
An institutional investor recently bought a new position in Metsera stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Metsera, Inc. (NASDAQ:MTSR - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 9,126 shares of the company's stock, valued at approximately $248,000.
Metsera Company Profile
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Further Reading
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
